AbateN.Obesity and cardiovascular disease. Pathogenetic role of the metabolic syndrome and therapeutic implications.J Diabet Complications2000; 14: 154–74.
2.
WiecekA., KokotF., ChudekJ., AdamczakM.The adipose tissue—a novel endocrine organ of interest to the nephrologist.Nephrol Dial Transplant2002; 17: 191–5.
3.
TrayhurnP., BeattieJ.H.Physiological role of adipose tissue: White adipose tissue as an endocrine and secretory organ.Proc Nutr Soc2001; 60: 329–39.
4.
McCartyM.F.Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes and visceral obesity: Down-regulation with essential fatty acids, ethanol and pentoxyphilline.Med Hypotheses1999; 52: 465–77.
5.
FestaA., D'AgostinoR.Jr., WilliamsK., KarterA.J., Mayer–DavisE.J., TracyR.P.The relation of body fat mass and distribution to markers of chronic inflammation.Int J Obes Relat Metab Disord2001; 25: 1407–15.
6.
ForouhiN.G., SattarN., McKeigueP.M.Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians.Int J Obes Relat Metab Disord2001; 25: 1327–31.
7.
PannacciulliN., CantatoreF.P., MinennaA., BellaciccoM., GiorginoR., De PergolaG.C-reactive protein is independently associated with total body fat, central fat, and insulin resistance in adult women.Int J Obes Relat Metab Disord2001; 25: 1416–20.
8.
StenvinkelP., LonnqvistF., SchallingM.Molecular studies of leptin: Implications for renal disease.Nephrol Dial Transplant1999; 14: 1103–12.
9.
WybranskaI., PankiewiczJ., WojtowiczA., Dembinska–KiecA.VEGF, insulin and leptin proliferative activity in endothelial and vascular smooth muscle cells [Abstract].Eur J Clin Invest1999; 29(Suppl 1): 104.
10.
StenvinkelP., LindholmB., LonnqvistF., KatzarskiK., HeimbürgerO.Increases in serum leptin levels during peritoneal dialysis are associated with inflammation and a decrease in lean body mass.J Am Soc Nephrol2000; 11: 1303–9.
11.
DonB.R., RosalesL.M., LevineN.W., MitchW., KaysenG.A.Leptin is a negative acute phase protein in chronic hemodialysis patients.Kidney Int2001; 59: 1114–20.
12.
ChungS.H., LindholmB., LeeH.B.Influence of initial nutritional status on continuous ambulatory peritoneal dialysis patient survival.Perit Dial Int2000; 20: 19–26.
13.
AvramM.M., SreedharaR., FeinP., OoK.K., ChattopadhyayJ., MittmanN.Survival on hemodialysis and peritoneal dialysis over 12 years with emphasis on nutritional parameters.Am J Kidney Dis2001; 37(Suppl 2): S77–80.
14.
FernströmA., HylanderB., MoritzA., JacobssonH., RossnerS.Increase of intra-abdominal fat in patients treated with continuous ambulatory peritoneal dialysis.Perit Dial Int1998; 18: 166–71.
15.
HeimbürgerO., LonnqvistF., DanielssonA., NordenstromJ., StenvinkelP.Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure.J Am Soc Nephrol1997; 8: 1423–30.
16.
FleischmannE., TealN., DudleyJ., MayW., BowerJ.D., SalahudeenA.K.Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients.Kidney Int1999; 55: 1560–7.
17.
JohnsonD.W., HerzigK.A., PurdieD.M., ChangW., BrownA.M., RigbyR.J.Is obesity a favorable prognostic factor in peritoneal dialysis patients?Perit Dial Int2000; 20: 715–21.
18.
AslamN., BernardiniJ., FriedL., PirainoB.Large body mass index does not predict short-term survival in peritoneal dialysis patients.Perit Dial Int2002; 22: 191–6.
19.
KaizuY., TsunegaY., YoneyamaT., SakaoT., HibiI., MiyajiK.Overweight as another nutritional risk factor for the long-term survival of non-diabetic hemodialysis patients.Clin Nephrol1998; 50: 44–50.
